Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Inc.

www.biogen.com

Latest From Biogen Inc.

LifeArc CEO: UK Charity Is Cashing In Its Keytruda ‘Jackpot’ To Expand R&D Focus

The CEO of LifeArc tells Scrip why the UK-based medical research charity has decided to monetize a part of its royalty interest in Merck’s hugely successful cancer drug, Keytruda.

Deals Research & Development

UK Rare Disease Drug Review Reform Urged As Spinraza Finally Gets NICE OK

It has taken 17 months of negotiations but soon 600-1,200 people in the UK may be able to get Biogen's spinal muscular atrophy therapy now that an access agreement has been inked.

Health Technology Assessment Market Access

Joy For SMA Patients As NICE And Biogen Break Spinraza Deadlock

Between 600-1,200 people in England and Wales may be able to get Spinraza now that after 17 months of negotiations "appropriate flexibility" has led to an access agreement.

Health Technology Assessment Market Access

The Eye Travels Wide: ProQR’s Bid For Leadership In The Genetics Of Sight

How did a youthful vendor of IT services, faced with a personal exposure to crippling illness, attract some of the best minds in biotech to launch a company with a then-untested RNA technology that today is a contender for leadership in the rarified space of inherited retinal disease? The answer may lie in the ambitiously definitive name that 36-year-old founder Daniel de Boer gave to his enterprise with a mission: ProQR – an active synonym for finding cures.

C-Suite Speaks Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Biogen Idec Inc.
  • Biogen Inc.
  • Idec Pharmaceutical Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Biogen Inc.
  • Senior Management
  • Michel Vounatsos, CEO
    Jeffrey Capello, EVP, CFO
    Alfred W Sandrock, Jr., MD, PhD, EVP, CMO
    Michael Ehlers, MD, PhD, EVP, R&D
    Daniel Karp, EVP, Corp. Dev.
    Chirfi Guindo, EVP & Head, Global Mktg.
  • Contact Info
  • Biogen Inc.
    Phone: (617) 679-2000
    225 Binney St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register